Veracyte, Inc. reports developments in cancer diagnostics, with recurring updates centered on its Veracyte Diagnostics Platform and genomic tests used in prostate, thyroid, bladder, and breast cancer. Company news frequently covers Decipher Prostate, Decipher Bladder, Afirma, Prosigna, and development work in whole-genome minimal residual disease and multi-omics applications.
Veracyte updates commonly include quarterly financial results, testing revenue and volume trends, clinical evidence presented at oncology and urology meetings, real-world data analyses, product-development capabilities, and leadership roles tied to assay development, software, bioinformatics, and AI-enabled diagnostics.
Veracyte (Nasdaq:VCYT) will host an investor conference call and webcast on June 1, 2026 at 8:30 a.m. ET to discuss data from two phase III clinical trials using its Prosigna Breast and Decipher Prostate tests, including results from the OPTIMA and ENZAMET trials.
Professor Iain Macpherson will join the discussion. The live and replay webcasts will be accessible via Veracyte’s investor relations website.
Veracyte (NASDAQ:VCYT) will present new data from phase III OPTIMA and ENZAMET trials at the 2026 ASCO Annual Meeting. These studies evaluate how Prosigna Breast and Decipher Prostate genomic tests can guide chemotherapy and treatment intensification decisions in early breast cancer and metastatic prostate cancer.
Veracyte (Nasdaq:VCYT) will participate in two upcoming investor conferences. Management presents at the William Blair 46th Annual Growth Stock Conference in Chicago on June 2, 2026, and at the Jefferies Global Healthcare Conference in New York on June 4, 2026.
Both events feature live and replay webcasts via Veracyte’s investor relations site.
Veracyte (Nasdaq:VCYT) received Medicare MolDX coverage for its TrueMRD Monitoring Test in muscle-invasive bladder cancer (MIBC). The test is covered for recurrence monitoring after curative-intent treatment and becomes orderable on June 1, 2026, marking Veracyte’s first commercial molecular residual disease offering.
According to Veracyte, the whole-genome, tumor-informed TrueMRD platform showed a median detection of recurrence 131 days earlier than imaging in the PAGER study of 112 MIBC patients. The platform is also used in ongoing TOMBOLA and NEO-BLAST trials, supporting its role in evolving MIBC treatment and surveillance strategies.
Veracyte (Nasdaq: VCYT) reported Q1 2026 results: total revenue $139.1M (+21% YoY) and testing revenue $135.1M (+26% YoY). Decipher revenue grew 30% to $86.5M; Afirma grew 21% to $46.4M. GAAP net income was $28.7M and adjusted EBITDA was $42.8M (30.8% of revenue). Cash from operations was $35.2M; cash and short-term investments totaled $439.1M as of March 31, 2026. Company raised 2026 revenue guidance to $582M–$592M and testing revenue to $570M–$580M, and raised adjusted EBITDA margin guidance to >26%.
Veracyte (Nasdaq: VCYT) announced that more than 15 studies on the Decipher portfolio will be presented at the AUA 2026 meeting (May 15–18, Washington, D.C.).
Highlights include Decipher Bladder molecular subtyping data linking subtypes to outcomes and responses to neoadjuvant chemo‑immunotherapy, and national‑scale Decipher Prostate real‑world analyses powered by the Decipher GRID database with more than a decade of data. Veracyte will be at booth #3405.
Veracyte (Nasdaq: VCYT) will release first quarter 2026 financial results after market close on May 5, 2026.
Management will host a conference call and live webcast at 4:30 p.m. Eastern Time on May 5, 2026 to discuss results and provide a business update; a replay will be available on the company’s investor website.
Veracyte (Nasdaq: VCYT) named Kevin Haas, Ph.D., as Chief Development and Technology Officer, effective March 24, 2026. The newly created role will oversee end-to-end product development across assays, software, bioinformatics, and the product development program office to support MRD and multi-omics initiatives.
Dr. Haas brings more than 15 years of life sciences experience, including senior technology and bioinformatics leadership roles at Myriad and Counsyl, and holds a Ph.D. in chemical engineering from UC Berkeley.
Veracyte (Nasdaq: VCYT) reported strong fourth-quarter and full-year 2025 results: Q4 total revenue $140.6M (+19%), testing revenue $135.8M (+21%), and full-year revenue $517.1M (+16%).
GAAP net income was $41.1M for Q4 and $66.4M for 2025; cash from operations was $52.6M in Q4 and $136.3M for the year. The company reiterates 2026 revenue guidance of 10–13% ($570M–$582M) and expects adjusted EBITDA margin of ~25%.
Veracyte (Nasdaq: VCYT) will present more than 15 abstracts at the 2026 ASCO Genitourinary Cancers Symposium, Feb 26–28 in San Francisco, highlighting Decipher Prostate and Bladder tests and the upcoming TrueMRD™ MIBC test.
Presentations include SURE‑02 phase II results, HCRN GU 20-444 oral data, and multiple real-world Decipher and GRID analyses supporting clinical decision-making in urologic cancers.